Skip to main content
NASDAQ:BPMC

Blueprint Medicines Competitors

$93.88
-2.57 (-2.66 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$93.27
$96.95
50-Day Range
$90.95
$101.00
52-Week Range
$60.81
$125.61
Volume272,687 shs
Average Volume404,027 shs
Market Capitalization$5.48 billion
P/E Ratio17.32
Dividend YieldN/A
Beta0.92

Competitors

Blueprint Medicines (NASDAQ:BPMC) Vs. CVAC, HZNP, CTLT, ELAN, ALNY, and ZLAB

Should you be buying BPMC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Blueprint Medicines, including CureVac (CVAC), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), and Zai Lab (ZLAB).

CureVac (NASDAQ:CVAC) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares CureVac and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Blueprint Medicines41.08%43.72%33.35%

Analyst Ratings

This is a breakdown of recent recommendations for CureVac and Blueprint Medicines, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11302.40
Blueprint Medicines06712.64

CureVac currently has a consensus target price of $58.3333, indicating a potential downside of 49.88%. Blueprint Medicines has a consensus target price of $113.00, indicating a potential upside of 20.37%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Blueprint Medicines is more favorable than CureVac.

Earnings and Valuation

This table compares CureVac and Blueprint Medicines' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Blueprint Medicines$66.51 million82.35$-347,690,000.00($7.27)-12.91

CureVac has higher earnings, but lower revenue than Blueprint Medicines.

Summary

Blueprint Medicines beats CureVac on 9 of the 10 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Horizon Therapeutics Public and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Blueprint Medicines41.08%43.72%33.35%

Volatility and Risk

Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider and Institutional Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by insiders. Comparatively, 3.8% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Horizon Therapeutics Public and Blueprint Medicines' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion16.22$573.02 million$1.9448.35
Blueprint Medicines$66.51 million82.35$-347,690,000.00($7.27)-12.91

Horizon Therapeutics Public has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Horizon Therapeutics Public and Blueprint Medicines, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
Blueprint Medicines06712.64

Horizon Therapeutics Public currently has a consensus target price of $111.3636, indicating a potential upside of 18.74%. Blueprint Medicines has a consensus target price of $113.00, indicating a potential upside of 20.37%. Given Blueprint Medicines' higher probable upside, analysts clearly believe Blueprint Medicines is more favorable than Horizon Therapeutics Public.

Summary

Horizon Therapeutics Public beats Blueprint Medicines on 10 of the 15 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Catalent (NYSE:CTLT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Blueprint Medicines and Catalent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Catalent9.25%14.20%4.83%

Risk and Volatility

Blueprint Medicines has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Insider and Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Comparatively, 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Blueprint Medicines and Catalent's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million82.35$-347,690,000.00($7.27)-12.91
Catalent$3.09 billion5.62$173 million$1.8854.27

Catalent has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Blueprint Medicines and Catalent, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Catalent01702.88

Blueprint Medicines presently has a consensus price target of $113.00, indicating a potential upside of 20.37%. Catalent has a consensus price target of $125.1250, indicating a potential upside of 22.65%. Given Catalent's stronger consensus rating and higher possible upside, analysts clearly believe Catalent is more favorable than Blueprint Medicines.

Summary

Catalent beats Blueprint Medicines on 8 of the 14 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Blueprint Medicines and Elanco Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Elanco Animal Health-8.45%3.43%2.04%

Risk and Volatility

Blueprint Medicines has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Insider and Institutional Ownership

86.8% of Elanco Animal Health shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Comparatively, 0.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Blueprint Medicines and Elanco Animal Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million82.35$-347,690,000.00($7.27)-12.91
Elanco Animal Health$3.07 billion5.39$67.90 million$1.0633.03

Elanco Animal Health has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Blueprint Medicines and Elanco Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Elanco Animal Health13902.62

Blueprint Medicines presently has a consensus price target of $113.00, indicating a potential upside of 20.37%. Elanco Animal Health has a consensus price target of $33.1364, indicating a potential downside of 5.35%. Given Blueprint Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Blueprint Medicines is more favorable than Elanco Animal Health.

Summary

Blueprint Medicines beats Elanco Animal Health on 10 of the 15 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Blueprint Medicines and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Risk and Volatility

Blueprint Medicines has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Insider and Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Blueprint Medicines and Alnylam Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million82.35$-347,690,000.00($7.27)-12.91
Alnylam Pharmaceuticals$219.75 million72.69$-886,120,000.00($8.11)-16.76

Blueprint Medicines has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Blueprint Medicines and Alnylam Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Alnylam Pharmaceuticals08802.50

Blueprint Medicines presently has a consensus price target of $113.00, indicating a potential upside of 20.37%. Alnylam Pharmaceuticals has a consensus price target of $168.7333, indicating a potential upside of 24.17%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Alnylam Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Blueprint Medicines and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Zai LabN/AN/AN/A

Risk and Volatility

Blueprint Medicines has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Insider and Institutional Ownership

81.3% of Zai Lab shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Blueprint Medicines and Zai Lab's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million82.35$-347,690,000.00($7.27)-12.91
Zai Lab$12.98 million1,123.31$-195,070,000.00($3.03)-50.82

Zai Lab has lower revenue, but higher earnings than Blueprint Medicines. Zai Lab is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Blueprint Medicines and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Zai Lab00503.00

Blueprint Medicines presently has a consensus price target of $113.00, indicating a potential upside of 20.37%. Zai Lab has a consensus price target of $197.8460, indicating a potential upside of 28.48%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts clearly believe Zai Lab is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Zai Lab on 8 of the 15 factors compared between the two stocks.


Blueprint Medicines Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CureVac logo
CVAC
CureVac
0.7$116.38-5.5%$21.75 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.79-1.8%$21.08 billion$1.30 billion25.63Insider Selling
Catalent logo
CTLT
Catalent
1.7$102.02-0.7%$17.38 billion$3.09 billion64.98Analyst Revision
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$35.01-0.6%$16.56 billion$3.07 billion-61.42Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89-0.1%$15.97 billion$219.75 million-17.36Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$153.99-0.7%$14.58 billion$12.98 million-50.82Earnings Announcement
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.34-0.5%$14.13 billion$1.70 billion17.70
Grifols logo
GRFS
Grifols
1.3$18.69-0.3%$12.85 billion$5.71 billion16.69News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.00-0.0%$11.97 billion$2.32 billion59.50Earnings Announcement
Analyst Report
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.76-1.8%$11.75 billion$16.89 billion-2.92
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.25-0.6%$10.48 billion$8.60 billion-5.37
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.80-1.3%$10.06 billion$2.16 billion55.77Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$38.40-1.2%$9.89 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$198.29-0.2%$8.88 billion$1.45 billion18.76
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.13-0.9%$8.08 billion$40.56 million-15.87
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$155.50-0.7%$8.00 billion$3.34 million-20.19Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$73.05-0.3%$7.60 billion$87.99 million-86.96
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$110.29-0.5%$7.44 billion$103.71 million-25.12
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$135.63-2.5%$7.29 billion$14.98 million-16.52Upcoming Earnings
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.46-0.9%$6.07 billion$4.84 billion-757.54Earnings Announcement
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$75.13-1.2%$5.99 billion$380.83 million-9.61
Allakos logo
ALLK
Allakos
1.7$100.54-0.1%$5.39 billionN/A-36.69Analyst Downgrade
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.32-2.5%$5.26 billion$1.12 billion77.75Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$77.00-1.1%$5.04 billion$1.00 billion-11.67Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$33.85-1.2%$4.79 billion$150,000.00-15.97Earnings Announcement
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.2$63.60-2.0%$4.60 billion$4.31 million-2.20News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.27-0.6%$4.57 billionN/A-5.73Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.6$61.45-0.3%$4.30 billion$85.54 million0.00Insider Selling
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$53.06-16.6%$4.27 billionN/A-7.15Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$72.75-2.6%$4.25 billion$6.87 million-7.03
LEGN
Legend Biotech
1.3$30.90-4.2%$4.11 billion$64.39 million0.00Analyst Report
High Trading Volume
News Coverage
Gap Up
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.75-3.5%$3.98 billion$204.89 million-33.44
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.89-0.9%$3.70 billion$806.43 million-8.62
Alkermes logo
ALKS
Alkermes
1.2$22.08-0.8%$3.54 billion$1.17 billion-48.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$70.45-1.6%$3.46 billionN/A-20.07
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.72-0.9%$3.43 billion$117.91 million-11.30
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.23-2.5%$3.40 billion$339.08 million-12.34Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.19-4.3%$3.32 billion$114.62 million-7.33Analyst Report
Insider Selling
Arvinas logo
ARVN
Arvinas
1.7$67.24-0.5%$3.29 billion$42.98 million-26.27
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$110.73-2.8%$3.26 billionN/A-55.09
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$60.29-2.8%$3.23 billion$1.11 billion19.39
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.10-1.3%$3.01 billion$60,000.00-11.52Analyst Upgrade
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$79.07-0.9%$2.86 billion$26.52 million-6.97
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.29-0.9%$2.80 billion$644.77 million-10.46Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.93-0.1%$2.75 billion$80.43 million99.67
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.60-1.0%$2.71 billion$421.03 million21.69Analyst Report
Insmed logo
INSM
Insmed
1.2$26.04-0.7%$2.69 billion$136.47 million-10.02Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.5$38.00-0.0%$2.68 billion$306.98 million-5.44Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.40-1.3%$2.56 billionN/A-22.20Earnings Announcement
Analyst Revision
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.